Epigenomic Priming as an Immunotherapy Enhancer in Ovarian Cancer

Project: Research project

Project Details


we propose two translational
objectives embedded in the clinical trial:
Aim 1: Measure the antigen burden induced by
treatment with guadecitabine in human tumors in
relationship to clinical response.
Aim 2: Determine the anti-tumor activity of CD8+
effector T cells induced by treatment with
guadecitabine and pembrolizumab in relationship to
clinical response.
We will take advantage of the unique resource provided by the ready-to-activate investigator initiated phase II
clinical trial testing the combination of pembrolizumab and guadecitabine (SGI-110) in women with platinum
resistant OC and measure tumor antigen expression and immune activation in tumor biopsies obtained before
and after treatment.
Effective start/end date5/1/174/30/21


  • U.S. Army Medical Research and Materiel Command (W81XWH-17-1-0141)


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.